NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer’s Disease and Reinforcing Platform’s Strength Across Neurological Disorders
Beyond Air, Inc. (XAIR)
Company Research
Source: GlobeNewswire
BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company developing transformative treatments for complex neurological disorders, including Autism Spectrum Disorder (ASD), brain cancers, and Alzheimer’s disease, and a subsidiary of Beyond Air (NASDAQ: XAIR), proudly announces the publication of breakthrough research by its Chief Scientific Officer, Prof. Haitham Amal, in Translational Psychiatry, a peer-reviewed medical journal published by Nature Publishing Group. The article, which is titled, “Shared Early Molecular Mechanisms Revealed in P301S and 5xFAD Alzheimer's Disease Mouse Models,” presents compelling evidence of a novel mechanism in the early stages of Alzheimer’s disease (AD), offers new hope for the development of effective therapies for this devastating condition. A copy of the article is available on Translational Psychiatry website at (click here). Alzheimer’s disease is one of the most common and costly neurodegenerative disorders
Show less
Read more
Impact Snapshot
Event Time:
XAIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XAIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XAIR alerts
High impacting Beyond Air, Inc. news events
Weekly update
A roundup of the hottest topics
XAIR
News
- Beyond Air® Signs New International LungFit PH® Distribution Agreements, Most Notably in Germany and BrazilGlobeNewswire
- How a data and tech strategy fueled DoorDash's rise [Fortune]Fortune
- Beyond Air® Announces Transition of Chief Financial OfficerGlobeNewswire
- Beyond Air (NASDAQ:XAIR) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $11.00 price target on the stock.MarketBeat
- Beyond Air Inc (XAIR) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amid Operational ... [Yahoo! Finance]Yahoo! Finance
XAIR
Earnings
- 8/12/25 - Miss
XAIR
Sec Filings
- 12/19/25 - Form DEF
- 12/16/25 - Form 424B3
- 12/16/25 - Form EFFECT
- XAIR's page on the SEC website